Tai Shu-Yu, Chien Chen-Yu, Wu Deng-Chyang, Lin Kun-Der, Ho Bo-Lin, Chang Yu-Han, Chang Yang-Pei
Department of Family Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.
Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan.
PLoS One. 2017 Feb 15;12(2):e0171006. doi: 10.1371/journal.pone.0171006. eCollection 2017.
Concerns have been raised regarding the potential association between proton pump inhibitor (PPI) use and dementia.
This study aimed to examine this association in an Asian population.
Patients initiating PPI therapy between January 1, 2000 and December 31, 2003 without a prior history of dementia were identified from Taiwan's National Health Insurance Research Database. The outcome of interest was all-cause dementia. Cox regression models were applied to estimate the hazard ratio (HR) of dementia. The cumulative PPI dosage stratified by quartiles of defined daily doses and adjusted for baseline disease risk score served as the primary variables compared against no PPI use.
We analyzed the data of 15726 participants aged 40 years or older and free of dementia at baseline. PPI users (n = 7863; average follow-up 8.44 years) had a significantly increased risk of dementia over non-PPI users (n = 7863; average follow-up 9.55 years) (adjusted HR [aHR] 1.22; 95% confidence interval: 1.05-1.42). A significant association was observed between cumulative PPI use and risk of dementia (P for trend = .013). Subgroup analysis showed excess frequency of dementia in PPI users diagnosed with depression (aHR 2.73 [1.91-3.89]), hyperlipidemia (aHR 1.81 [1.38-2.38]), ischemic heart disease (aHR 1.55 [1.12-2.14]), and hypertension (aHR 1.54 [1.21-1.95]).
An increased risk for dementia was identified among the Asian PPI users. Cumulative PPI use was significantly associated with dementia. Further investigation into the possible biological mechanisms underlying the relationship between dementia and PPI use is warranted.
质子泵抑制剂(PPI)的使用与痴呆症之间的潜在关联引发了人们的关注。
本研究旨在调查亚洲人群中的这种关联。
从台湾国民健康保险研究数据库中识别出2000年1月1日至2003年12月31日开始接受PPI治疗且无痴呆症病史的患者。感兴趣的结局是全因性痴呆。应用Cox回归模型估计痴呆症的风险比(HR)。将按限定日剂量四分位数分层并根据基线疾病风险评分进行调整的累计PPI剂量作为主要变量,与未使用PPI的情况进行比较。
我们分析了15726名40岁及以上且基线时无痴呆症的参与者的数据。PPI使用者(n = 7863;平均随访8.44年)患痴呆症的风险比非PPI使用者(n = 7863;平均随访9.55年)显著增加(调整后HR [aHR] 1.22;95%置信区间:1.05 - 1.42)。观察到累计使用PPI与痴呆症风险之间存在显著关联(趋势P值 = 0.013)。亚组分析显示,被诊断患有抑郁症(aHR 2.73 [1.91 - 3.89])、高脂血症(aHR 1.81 [1.38 - 2.38])、缺血性心脏病(aHR 1.55 [1.12 - 2.14])和高血压(aHR 1.54 [1.21 - 1.95])的PPI使用者中痴呆症发生率过高。
在亚洲PPI使用者中发现痴呆症风险增加。累计使用PPI与痴呆症显著相关。有必要进一步研究痴呆症与PPI使用之间关系的潜在生物学机制。